Tampa biotech secures $50M to fund Phase 3 cancer trial
Funding supports a Phase 3 cancer therapy program and extends runway into 2028.
Funding supports a Phase 3 cancer therapy program and extends runway into 2028.
The award adds to XTEND’s contract pipeline as it scales toward a public listing.
Three communities add new housing across North Tampa and Pasco’s growth corridor.
Blue Owl moves to acquire a Tampa healthcare REIT in a $2.4B deal.